Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Elicio Therapeutics

03/08/2026 12:16

Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Elicio Therapeutics Inc is for a loss of 54 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Elicio Therapeutics Inc is $23.00, about 721.4% above its last closing price of $2.80
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.46
-0.46
-0.65
Missed
-39.8
Dec. 31 2026
-0.45
-0.44
-0.45
Missed
-1.1
Sep. 30 2025
-0.55
-0.55
-0.60
Missed
-9.1​
Jun. 30 2025
-0.69
-0.68
-0.66
Beat
3.7
​​Mar. 31 2025
-0.82
-0.83
-0.87
Missed
-4.8
Dec. 31 2024
-0.87
-1.02
Missed
-16.6​
Sep. 30 2024
-0.71
-0.73
-1.39
Missed
-90.4
Jun. 30 2024
-0.96
-0.96
-0.64
Beat
33.3
This summary was machine generated August 3 at 11:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)